dr. wang on unique properties of kte-x19 in relapsed/refractory mcl
Published 4 years ago • 94 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
0:47
dr. wang on the safety profile of kte-x19 in mcl
-
1:04
dr. wang on the safety profile of brexucabtagene autoleucel in relapsed/refractory mcl
-
1:20
dr. wang on the safety and efficacy of kte-x19 in r/r mcl
-
2:07
dr. wang discusses the treatment of relapsed/refractory mcl
-
1:31
dr. wang on the efficacy of kte-x19 in low- and high-risk r/r mcl
-
1:29
dr. wang on the utility of car t-cell therapy in relapsed/refractory mcl
-
1:29
dr. wang on the impact of kte-x19 on outcomes in higher- versus lower-risk mcl
-
1:20
dr. wang on challenges treating patients with relapsed/refractory mcl
-
50:04
mantle cell lymphoma: from current treatments to future innovations(podcast)
-
10:42
understanding mantle cell lymphoma with jia ruan, md, ph.d.
-
42:29
mantle cell lymphoma (case studies)
-
1:11
dr. wang on comparative analysis of kte-x19 in higher- versus lower-risk r/r mcl
-
0:55
dr. wang on the evolution of treatment in mcl
-
1:20
dr. goy the evolution of treatment in relapsed/refractory mcl
-
1:10
dr. miklos on the safety profile of kte-x19 in mcl
-
0:54
dr. wang on updated data with single-agent acalabrutinib in mcl
-
3:54
zuma-2: outcomes of r/r mcl patients who progressed within 24 months of diagnosis
-
1:59
dr. wang on ongoing research in mcl
-
1:35
dr. lee on b-cell receptor targeting in relapsed/refractory mcl
-
1:29
dr. miklos on development process for kte-x19 in mcl
-
1:25
dr. lee on early efficacy data with cirmtuzumab/ibrutinib in relapsed/refractory mcl
-
1:08
dr. wang discusses the future of treatment in mcl